Sai Parenteral's Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 5,214,144 (50%) | — | ₹20,439 Cr |
| NII (HNI) | — | 1,564,243 (15%) | — | ₹6,132 Cr |
| Retail | — | 3,649,901 (35%) | — | ₹14,308 Cr |
| Σ Total | — | 10,428,288 (100%) | — | ₹408,789 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹193,648 |
| S-HNI (Min) | 14 | 532 | ₹208,544 |
| B-HNI (Min) | 67 | 2,546 | ₹998,032 |
Financial Statements Amount in ₹ Crore
| Metric | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 89 | 164 | 155 |
| EBITDA | 16 | 39 | 32 |
| Profit After Tax | 8 | 14 | 8 |
| Net Worth | 209 | 96 | 76 |
| Total Assets | 376 | 272 | 268 |
| Reserves & Surplus | 189 | 80 | 61 |
| Total Borrowing | 76 | 94 | 119 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Capacity expansion and upgradation of manufacturing facilities – 110.80
- Establishment of a new R&D Centre; – 18.02
- Repayment / prepayment of certain outstanding borrowings – 14.30
- Repayment / prepayment of certain outstanding borrowings – 33.00
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and – 35.64
- General corporate purposes –
Company Overview
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
- Diversified generic formulations player with an established track record.
- Strategically located and accredited Manufacturing Facilities.
- Strong focus on CDMO business.
- Well-established distribution network in India and overseas.
- Track record of value-accretive acquisitions.
- Experienced Promoters and Senior Management with extensive domain knowledge.